All In Biotech

NDA 009435 · Fresenius Kabi USA

Nesacaine-Mpf

Chloroprocaine Hydrochloride · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 2, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1955

Mar 11, 1955

Approved uses

1

Original approval plus efficacy supplements

Registered trials

44

7 Phase 3, 4 recruiting

FAERS reports

34

20 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2024.

INDICATIONS & USAGE Nesacaine 1% and 2% Injections, in multidose vials with methylparaben as preservative, are indicated for the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia. Nesacaine-MPF 2% and 3% Injections, in single dose vials without preservative and without EDTA, are indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. Nesacaine and Nesacaine-MPF Injections are not to be used for subarachnoid administration.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 11, 1955 Original approval · Type 1 - New Molecular Entity · priority review
6 products under this application
  • NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 3% · INJECTABLE, INJECTION · Prescription · TE AP
  • NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Discontinued
  • NESACAINE · CHLOROPROCAINE HYDROCHLORIDE 1% · INJECTABLE, INJECTION · Discontinued
  • NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP
  • NESACAINE-MPF · CHLOROPROCAINE HYDROCHLORIDE 3% · INJECTABLE, INJECTION · Discontinued
  • NESACAINE · CHLOROPROCAINE HYDROCHLORIDE 2% · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloroprocaine" as an intervention, any sponsor and status, largest first.

All 44 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7
  • hypotension3
  • product label confusion3
  • anaesthetic complication2
  • areflexia2
  • arthralgia2
  • back pain2
  • bradycardia2
  • drug dose omission2
  • dyspnoea2
  • headache2
  • hypoaesthesia2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20062
20101
20112
20122
20133
20143
20151
20161
20173
20181
20191
20204
20214
20221
20233

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 131 on PubMed

Sponsor: Fresenius Kabi USA · Also marketed as Nesacaine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.